Research progress in tumor targeted immunotherapy

被引:20
作者
Fang, Yuelin [1 ]
Yu, Aihua [1 ]
Ye, Lei [1 ]
Zhai, Guangxi [1 ]
机构
[1] Shandong Univ, Sch Pharmaceut Sci, Minist Educ, Dept Pharmaceut,Key Lab Chem Biol, Jinan, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer immunotherapy; immune checkpoints; nanoparticles; targeted therapy; tumor-associated macrophages; tumor-associated fibroblasts; Treg cells; FIBROBLAST ACTIVATION PROTEIN; JUNCTION G/GEJ ADENOCARCINOMA; PLUS PEMBROLIZUMAB P; MONOCLONAL-ANTIBODY; PANCREATIC-CANCER; PATIENTS PTS; T-CELLS; PHASE-II; TGF-BETA; MACROPHAGES;
D O I
10.1080/17425247.2021.1882992
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Compared with traditional cancer treatment methods, tumor-targeted immunotherapy can combine targeted therapy and immunotherapy with long-lasting responses to achieve synergistic therapy, which brings hope to the complete cure of cancer. Areas covered This review summarizes the newest and most up-to-date advances in tumor-targeted immunotherapy, including tumor-associated macrophages (TAMs) targeted immunotherapy, regulatory T (Treg) cells targeted immunotherapy, tumor-associated fibroblasts (TAFs) targeted immunotherapy and immune checkpoints targeted immunotherapy. Expert opinion Immunotherapy can restore anti-tumor immunity in the tumor microenvironment and produce a lasting immune surveillance effect. Smart multifunctional nano delivery system can effectively combine targeted therapy with immunotherapy, which has attracted extensive attention. With the deepening of research, more and more tumor-targeted immunotherapy enter into the clinical trial phases, especially antibodies and inhibitors. Tumor-targeted immunotherapy is a promising approach for conquering cancer and bringing hope for human health.
引用
收藏
页码:1067 / 1089
页数:23
相关论文
共 146 条
[1]   Big opportunities for small molecules in immuno-oncology [J].
Adams, Jerry L. ;
Smothers, James ;
Srinivasan, Roopa ;
Hoos, Axel .
NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) :603-622
[2]   Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy [J].
Ahmad, Shamim ;
Abu-Eid, Rasha ;
Shrimali, Rajeev ;
Webb, Mason ;
Verma, Vivek ;
Doroodchi, Atbin ;
Berrong, Zuzana ;
Samara, Raed ;
Rodriguez, Paulo C. ;
Mkrtichyan, Mikayel ;
Khleif, Samir N. .
CANCER RESEARCH, 2017, 77 (08) :1892-1904
[3]   STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes [J].
Andersen, Morten Norgaard ;
Etzerodt, Anders ;
Graversen, Jonas H. ;
Holthof, Lisa C. ;
Moestrup, Soren K. ;
Hokland, Marianne ;
Moller, Holger J. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) :489-502
[4]   Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation [J].
Anderson, Ana C. ;
Joller, Nicole ;
Kuchroo, Vijay K. .
IMMUNITY, 2016, 44 (05) :989-1004
[5]   Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression [J].
Bak, S. Peter ;
Walters, Julie Jo ;
Takeya, Motohiro ;
Conejo-Garcia, Jose R. ;
Berwin, Brent L. .
CANCER RESEARCH, 2007, 67 (10) :4783-4789
[6]   CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].
Beatty, Gregory L. ;
Chiorean, Elena G. ;
Fishman, Matthew P. ;
Saboury, Babak ;
Teitelbaum, Ursina R. ;
Sun, Weijing ;
Huhn, Richard D. ;
Song, Wenru ;
Li, Dongguang ;
Sharp, Leslie L. ;
Torigian, Drew A. ;
O'Dwyer, Peter J. ;
Vonderheide, Robert H. .
SCIENCE, 2011, 331 (6024) :1612-1616
[7]   Rational design and development of a peptide inhibitor for the PD-1/PD-Ll interaction [J].
Boohaker, Rebecca J. ;
Sambandam, Vijaya ;
Segura, Isaac ;
Miller, James ;
Suto, Mark ;
Xu, Bo .
CANCER LETTERS, 2018, 434 :11-21
[8]   Metal-Organic Framework-Based Nanomedicine Platforms for Drug Delivery and Molecular Imaging [J].
Cai, Wen ;
Chu, Cheng-Chao ;
Liu, Gang ;
Wang, Yi-Xiang J. .
SMALL, 2015, 11 (37) :4806-4822
[9]   Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy [J].
Cannarile, Michael A. ;
Weisser, Martin ;
Jacob, Wolfgang ;
Jegg, Anna-Maria ;
Ries, Carola H. ;
Ruettinger, Dominik .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[10]   CpG-coated prussian blue nanoparticles-based photothermal therapy combined with anti-CTLA-4 immune checkpoint blockade triggers a robust abscopal effect against neuroblastoma [J].
Cano-Mejia, Juliana ;
Shukla, Anshi ;
Ledezma, Debbie K. ;
Palmer, Erica ;
Villagra, Alejandro ;
Fernandes, Rohan .
TRANSLATIONAL ONCOLOGY, 2020, 13 (10)